Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4 ...

Filoviruses are among the globe's most lethal—indeed, so dangerous they can be handled only in high-security laboratories.

Jenny Strasburg is a reporter in London, where she writes for The Wall Street Journal about oil and gas, climate, the ...

Major drug companies are beginning to deliver their first-quarter readouts to Wall Street analysts, revealing their ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations ...

Major drugmakers were a standout on a tumultuous day of corporate earnings on Thursday, beating expectations even as they ...